| Statin use and reduced cancer-related mortality. | |
| | |
MedLine Citation:
|
PMID: 23134381 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: A reduction in the availability of cholesterol may limit the cellular proliferation required for cancer growth and metastasis. We tested the hypothesis that statin use begun before a cancer diagnosis is associated with reduced cancer-related mortality. METHODS: We assessed mortality among patients from the entire Danish population who had received a diagnosis of cancer between 1995 and 2007, with follow-up until December 31, 2009. Among patients 40 years of age or older, 18,721 had used statins regularly before the cancer diagnosis and 277,204 had never used statins. RESULTS: Multivariable-adjusted hazard ratios for statin users, as compared with patients who had never used statins, were 0.85 (95% confidence interval [CI], 0.83 to 0.87) for death from any cause and 0.85 (95% CI, 0.82 to 0.87) for death from cancer. Adjusted hazard ratios for death from any cause according to the defined daily statin dose (the assumed average maintenance dose per day) were 0.82 (95% CI, 0.81 to 0.85) for a dose of 0.01 to 0.75 defined daily dose per day, 0.87 (95% CI, 0.83 to 0.89) for 0.76 to 1.50 defined daily dose per day, and 0.87 (95% CI, 0.81 to 0.91) for higher than 1.50 defined daily dose per day; the corresponding hazard ratios for death from cancer were 0.83 (95% CI, 0.81 to 0.86), 0.87 (95% CI, 0.83 to 0.91), and 0.87 (95% CI, 0.81 to 0.92). The reduced cancer-related mortality among statin users as compared with those who had never used statins was observed for each of 13 cancer types. CONCLUSIONS: Statin use in patients with cancer is associated with reduced cancer-related mortality. This suggests a need for trials of statins in patients with cancer. |
| | |
Authors:
|
Sune F Nielsen; Børge G Nordestgaard; Stig E Bojesen |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The New England journal of medicine Volume: 367 ISSN: 1533-4406 ISO Abbreviation: N. Engl. J. Med. Publication Date: 2012 Nov |
Date Detail:
|
Created Date: 2012-11-08 Completed Date: 2012-11-19 Revised Date: 2013-02-25 |
Medline Journal Info:
|
Nlm Unique ID: 0255562 Medline TA: N Engl J Med Country: United States |
Other Details:
|
Languages: eng Pagination: 1792-802 Citation Subset: AIM; IM |
Affiliation:
|
Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Cardiovascular Diseases / complications, epidemiology Cause of Death Denmark / epidemiology Diabetes Complications / epidemiology Diabetes Mellitus / epidemiology Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use* Incidence Male Middle Aged Neoplasms / complications, mortality*, prevention & control Proportional Hazards Models |
| Chemical | |
Reg. No./Substance:
|
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors |
| Comments/Corrections | |
Comment In:
|
N Engl J Med. 2013 Feb 7;368(6):574
[PMID:
23388013
]
N Engl J Med. 2012 Nov 8;367(19):1848-50 [PMID: 23134387 ] N Engl J Med. 2013 Feb 7;368(6):574-5 [PMID: 23388014 ] N Engl J Med. 2013 Feb 7;368(6):575-6 [PMID: 23388015 ] N Engl J Med. 2013 Feb 7;368(6):576-7 [PMID: 23388012 ] N Engl J Med. 2013 Feb 7;368(6):576 [PMID: 23388016 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: "If I had only known"--on choice and uncertainty in the ICU.
Next Document: Reduced mortality with hospital pay for performance in England.